3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
4
Stomach Neoplasms
3
Triple Negative Breast Neoplasms
2
Advanced Solid Tumor
2
Advanced Cancer
2
Solid Tumor, Adult
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Mouth Neoplasms
1
Extensive Stage Small Cell Lung Cancer
1
Esophageal Squamous Cell Carcinoma
1
Cytochrome P450 Interaction
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Malignancies
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
pembrolizumab
26
Nivolumab
18
enfortumab vedotin
7
avelumab
6
atezolizumab
6
Ipilimumab
6
Magnetic Resonance Spectroscopy
5
fludarabine
4
cabozantinib
4
Gemcitabine
4
Cyclophosphamide
4
Carboplatin
4
Specimen Handling
3
Interleukin-2
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
aldesleukin
2
Platinum
2
Pemetrexed
2
Paclitaxel
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Disulfides
2
Cisplatin
2
Albumin-Bound Paclitaxel
2
vinflunine
1
veliparib
1
valrubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Transitional Cell
×
apatinib
×
Clear all
NCT03407976
2020-07-15
APPEASE
University of Utah
Phase 1
Terminated
5 enrolled